Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Acute megakaryoblastic leukemia: experience of GIMEMA trials

Abstract

The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them, 24 were AMeL. The incidence of AMeL among AML patients enrolled in GIMEMA trials was 0.6% (24/3603). Diagnosis was based on morphological criteria. Out of 11 cytogenetic studies performed two presented chromosome 3 abnormalities. Twelve patients (50%) reached a CR, five (21%) died in induction and seven (27%) were unresponsive. The median duration of CR was 35 weeks (range 10–441). Seven patients underwent transplantation procedures (1 BMT, 4 aBMT, 2 aPBSCT). Four patients died in CR due to chemotherapy-related complications. Comparing the CR rate between AMeL and the other cases of AML enrolled in GIMEMA trials, no differences were observed. These results were mirrored for different age groups. The median survival was 40 weeks. At present, after a follow-up of a minimum of 2 years, only two patients are alive in CR, all the others having died. A 5-year Kaplan–Meier curve shows a disease-free survival of 17% and an actuarial overall survival of 10%. AMeL is a rare form of AML. The CR duration and the overall survival in this group of patients are very poor, even if similar to those observed in other AML. Furthermore, a high number of deaths in CR were observed. On the basis of these data, a specific therapeutic approach, possibly with innovative treatments, should be evaluated.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Von Boros J, Korenyi A . Uber einen fall von akuter megakaryocyblasten-leukamie, zugleich einige bemerkungen zum Problem der akuten leukemie Z Klin Med 1931 118: 679–718

    Google Scholar 

  2. Gassmann W, Loffler H . Acute megakaryoblastic leukemia Leuk Lymphoma 1995 18 (Suppl. 1): 69–73

    Article  Google Scholar 

  3. Pui C-H, Williams DL, Scarborough V, Jackson CW, Price R, Murphy S . Acute megakaryoblastic leukemia associated with intrinsic platelet dysfunction and constitutional ring 2 chromosome in a young boy Br J Haematol 1982 50: 191–200

    Article  CAS  PubMed  Google Scholar 

  4. San Miguel JF, Gonzalez M, Canizo MC, Ojeda E, Orfao A, Caballero MD, Moro MJ, Fisac P, Lopez Borrasca A . Leukemia with megakaryoblastic involvement: clinical, hematological and immunological characteristics Blood 1988 72: 402–407

    CAS  PubMed  Google Scholar 

  5. Nichols CR, Hoffman R, Einhorn LH, Williams SD, Wheeler LA, Garnick MB . Hematologic malignancies associated with primary mediastinal germ-cell tumors Ann Intern Med 1985 102: 603–609

    Article  CAS  PubMed  Google Scholar 

  6. Nichols CR, Hoffman R, Glant MD, Goheen M . Malignant disorders of megakaryocytes associated with primary germ cell tumors Prog Clin Biol Res 1986 215: 347–353

    CAS  PubMed  Google Scholar 

  7. Domingo A, Romagosa V, Callis M, Vivancos P, Guionnet N, Soler J . Mediastinal germ cell tumor and acute megakaryoblastic leukemia Ann Intern Med 1989 111: 539

    Article  CAS  PubMed  Google Scholar 

  8. Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM . Acute megacaryocytic leukemia: the Eastern Cooperative Oncology Group experience Blood 2000 96: 2405–2411

    CAS  PubMed  Google Scholar 

  9. Ruiz-Arguelles GJ, Lobato-Mendizabal E, San-Miguel JF, Gonzalez M, Caballero MD, Ruiz-Arguelles A, Orfao A, Gomez-Almaguer D, Vidriales B, Ruiz-Reyes G . Long-term treatment results for acute megakaryoblastic leukemia patients: a multicentre study Br J Haematol 1992 82: 671–675

    Article  CAS  PubMed  Google Scholar 

  10. Ribeiro RC, Oliveira MS, Fairclough D, Hurwitz C, Mirro J, Behm FG, Head D, Silva ML, Raimondi SC, Crist WM . Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases Leuk Lymphoma 1993 10: 299–306

    Article  CAS  PubMed  Google Scholar 

  11. Bernstein J, Dastugue N, Haas OA, Harbott J, Heerema NA, Huret JL, Landman-Parker J, LeBeau MM, Leonard C, Mann G, Pages MP, Perot C, Pirc-Danoewinata H, Roitzheim B, Rubin CM, Slociak M, Viguie F . Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group Leukemia 2000 14: 216–218

    Article  CAS  PubMed  Google Scholar 

  12. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, Srivastava DK, Rubnitz JE, Bowman L, Pui CH, Ribeiro RC . Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience Blood 2001 97: 3727–3732

    Article  CAS  PubMed  Google Scholar 

  13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C . Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French–American–British Cooperative Group Ann Intern Med 1985 103: 460–462

    Article  CAS  PubMed  Google Scholar 

  14. Petti MC, Mandelli F, Avvisati G, Covelli A, Amadori S, Liso V, Leone G, De Laurenzi A, Leoni P, Neri A . High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA Eur J Haematol 1989 42: 24–31

    Article  CAS  PubMed  Google Scholar 

  15. Mandelli F, Vegna ML, Avvisati G, Amadori S, Spadea A, Cacciola E, Cantore N, De Laurenzi A, De Rosa C, Fioritoni G . A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA Ann Hematol 1992 64: 166–172

    Article  CAS  PubMed  Google Scholar 

  16. Resegotti L . Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience Leukemia 1992 6 (Suppl. 2): 72–75

    Google Scholar 

  17. Montillo M, Tedeschi A, Pagano L, Venditti A, Ferrara F, Fabris P, Martino B, Musso M, De Rosa G, Specchia G, Monaco M, Sparaventi G, Spadea A, Palmas A, Deplano W, Manna A, Melillo L, Miraglia E, Mirto S, Mandelli F . Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto Br J Haematol 2000 111: 334–337

    Article  CAS  PubMed  Google Scholar 

  18. Zittoun R, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Ferrini PR, Visani G, Caronia F, Stryckmans P . EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML) Leuk Lymphoma 1994 13 (Suppl. 1): 101

    Article  Google Scholar 

  19. Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC . Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group Leukemia 1992 6 (Suppl. 2): 76–77

    Google Scholar 

  20. Zittoun R, Suciu S, De Witte T, Resegotti L, Liso V, Wikllemze R, Belharri A, Amadori S, Giustolisi G, Labar B, Fioritoni G, Rossi ferrini P, Leone G, Keating J, Fazi P, Dardenne M, Solbu G, Mandelli F . Comparison of three intercalating agents in induction and consolidation in acute myelogeneous leukemia (AML) followed by autologous or allogeneic transplantation: preliminary results of the EORTC-GIMEMA AML-10 randomized trial Blood 1999 94 (Suppl. 1): (Abstr. 2923)

  21. Zucker-Franklin D, Yang JS, Grusky G . Characterization of glycoprotein IIb/IIIapositive cells in human umbilical cord blood: their potential usefulness as megakaryocyte progenitors Blood 1992 79: 347–355

    CAS  PubMed  Google Scholar 

  22. Helleberg C, Knudsen H, Hansen PB, Nikolajsen K, Kjaersgaard E, Ralfkiaer E, Johnsen HE . CD34+ megakaryoblastic leukemic cells are CD38, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? Leukemia 1997 11: 830–834

    Article  CAS  PubMed  Google Scholar 

  23. Ruiz-Arguelles GJ, Marin-Lopez A, Lobato-Mendizabal E, Ruiz-Arguelles A, Nichols WL, Katzman JA . Acute megakaryoblastic leukemia: a prospective study of its identification and treatment Br J Haematol 1986 62: 55–63

    Article  CAS  PubMed  Google Scholar 

  24. Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J . Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group Leukemia 1996 10: 1677–1686

    CAS  PubMed  Google Scholar 

  25. Sastre JL, Ulibarrena C, Armesto A, del Rio D, Bello JA, Rodriguez M, Garcia Torremocha S, Vazquez O . Testicular granulocytic sarcoma as a form of relapse in ap patient with acute megacaryoblastic leukemia Sangre 1998 43: 248–250

    CAS  PubMed  Google Scholar 

  26. Lorsbach RB, Folkerth RD, Pinkus GS . Relapse of acute myelogenous leukemia as a cerebellar myeloblastoma showing megacaryoblastic differentiation Mod Pathol 1999 12: 1186–1191

    CAS  PubMed  Google Scholar 

  27. Mehta AB, Baughan AS, Catovsky D, Goldman JM, Johnson SA, Galton DA . Reversal of marrow fibrosis in acute megakaryoblastic leukaemia after remission-induction and consolidation chemotherapy followed by bone marrow transplantation Br J Haematol 1983 53: 445–449

    Article  CAS  PubMed  Google Scholar 

  28. Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S, Dufour C, Ferrara GB, Abbondandolo A, Dini G, Bacigalupo A, Cancedda R, Quarto R . Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients Exp Hematol 1999 27: 1460–1466

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pagano, L., Pulsoni, A., Vignetti, M. et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia 16, 1622–1626 (2002). https://doi.org/10.1038/sj.leu.2402618

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402618

Keywords

This article is cited by

Search

Quick links